Dr Reddy’s Launches Lamotrigine Extended-Release Tablets in US

26 Jun 2013 Evaluate

Dr Reddy's Laboratories has launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal XR (lamotrigine) in the US market on June 25, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Lamotrigine XR tablets.

The Lamictal XR brand and generic had combined US sales of approximately $300.5 Million MAT for the most recent twelve months ending in April 2013 according to IMS Health.

Dr Reddy's Lamotrigine XR Tablets 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg are available as unit of use bottles of 30s.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1280.95 0.55 (0.04%)
16-Dec-2025 14:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.00
Dr. Reddys Lab 1280.95
Cipla 1501.65
Zydus Lifesciences 919.00
Lupin 2091.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×